<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548753" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548753/" /><meta name="ncbi_pagename" content="Cyclosporine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Cyclosporine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Cyclosporine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/02/17" /><meta name="citation_pmid" content="31644062" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548753/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Cyclosporine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/02/17" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548753/" /><meta name="description" content="Cyclosporine is a calcineurin inhibitor and potent immunosuppressive agent used largely as a means of prophylaxis against cellular rejection after solid organ transplantation. Cyclosporine therapy can be associated with mild elevations in serum bilirubin and transient serum enzyme elevations, and to rare instances of clinically apparent cholestatic liver injury." /><meta name="og:title" content="Cyclosporine" /><meta name="og:type" content="book" /><meta name="og:description" content="Cyclosporine is a calcineurin inhibitor and potent immunosuppressive agent used largely as a means of prophylaxis against cellular rejection after solid organ transplantation. Cyclosporine therapy can be associated with mild elevations in serum bilirubin and transient serum enzyme elevations, and to rare instances of clinically apparent cholestatic liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548753/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Cyclosporine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548753/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D1D850466438100000000057101AC.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548753_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548753_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Cycloserine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Cyproheptadine/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548753_"><span class="title" itemprop="name">Cyclosporine</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 17, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Cyclosporine.OVERVIEW"><h2 id="_Cyclosporine_OVERVIEW_">OVERVIEW</h2><div id="Cyclosporine.Introduction"><h3>Introduction</h3><p>Cyclosporine is a calcineurin inhibitor and potent immunosuppressive agent used largely as a means of prophylaxis against cellular rejection after solid organ transplantation. Cyclosporine therapy can be associated with mild elevations in serum bilirubin and transient serum enzyme elevations, and to rare instances of clinically apparent cholestatic liver injury.</p></div><div id="Cyclosporine.Background"><h3>Background</h3><p>Cyclosporine (sye" kloe spor' in), also called cyclosporin A, is a cyclic polypeptide of 11 amino acids produced by a fungal species (Beauveria nivea) which has profound immunosuppressive properties, particularly affecting T cells and the cellular immune response. Cyclosporine acts as an inhibitor of calcineurin which is responsible for activating an important signal transduction pathway of T cell activation. The result of the inhibition is a decrease in maturation of T lymphocytes and reduction in lymphokine production, including IL-2. Cyclosporine was introduced into use in the United States in the early 1980s and rapidly became part of the primary regimen of immunosuppression after allogenic, solid organ transplantation. Current indications are for prevention of organ rejection after transplantation and for therapy of active and recalcitrant rheumatoid arthritis and psoriasis. Cyclosporine is available as capsules of 25 and 100 mg in generic forms and under the brand name of Sandimmune, and as a more reliably absorbed microemulsion formulation of 25 and 100 mg in generic forms and under the brand name of Neoral (2003). Cyclosporine is also available in solution for oral and for intravenous use. Because of variable absorption, the usual maintenance dose of cyclosporine varies greatly and proper dosing requires monitoring for drug levels, which is also important because of its many dose dependent side effects and drug-drug interactions. Common side effects of cyclosporine include headache, dizziness, paresthesias, neuropathy, tremor, hypertension, hyperlipidemia, nephropathy, acne, hirsutism and gum hyperplasia. Uncommon but potentially severe adverse events include renal failure, microangiopathic hemolytic anemia, neurotoxicity, serious and opportunistic infections, increase risk of malignancy and anaphylactic reactions. Oral and parenteral cyclosporine should be prescribed only by physicians experienced in immunosuppressive therapy and management of its complications.</p></div><div id="Cyclosporine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In several large clinical trials, initiation of cyclosporine therapy was associated with mild elevations in serum bilirubin levels, often without significant increases in serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> or alkaline phosphatase. Elevations in serum enzymes were also described, but less commonly. Recently, these complications appear to be less frequent, perhaps because of more careful dosing and monitoring of cyclosporine levels. Furthermore, in treatment of autoimmune diseases without the many complications of transplantation, cyclosporine therapy has been associated with mild serum alkaline phosphatase elevations in up to 30% of patients, but the abnormalities are asymptomatic, usually self-limiting and rarely require dose adjustment. In several case series, cyclosporine therapy has also been associated with biliary sludge and cholelithiasis. Isolated case reports of clinically apparent acute liver injury have been attributed to cyclosporine. The time to onset was within a few weeks of starting cyclosporine and the pattern of serum enzyme elevations was cholestatic. Recovery was prompt once cyclosporine was stopped and cases of chronic hepatitis or acute liver failure due to cyclosporine have not been reported.</p><p>Likelihood score: C (probable rare cause of clinically apparent liver injury).</p></div><div id="Cyclosporine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Cyclosporine undergoes extensive hepatic metabolism and because of its interaction with the cytochrome P450 system (CYP 3A4) is susceptible to severe drug-drug interactions. In animal models, cyclosporine decreases bile flow which may account for the mild hyperbilirubinemia that occurs with high doses.</p></div><div id="Cyclosporine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum bilirubin and liver enzyme elevations that can accompany cyclosporine use are usually mild, asymptomatic and self-limiting; if not, they usually resolve rapidly upon dose reduction. The rare instances of cholestatic liver injury due to cyclosporine usually resolve with discontinuation and most (but not all) patients can tolerate switching to tacrolimus. Cyclosporine has not been associated with instances of acute liver failure or vanishing bile duct syndrome.</p><p>Agents used specifically for the prophylaxis against allograft rejection include cyclosporine, mycophenolate mofetil, sirolimus and tacrolimus, as well as azathioprine and corticosteroids.</p><p>Drug Class: <a href="/books/n/livertox/Transplant_Drugs/">Transplant Agents</a>; <a href="/books/n/livertox/AntirheumaticAgents/">Antirheumatic Agents</a>, Major Immunosuppressive Agents; Dermatologic Agents</p><p>Other Drugs in the Class, Transplant Drugs: <a href="/books/n/livertox/Mycophenolate/">Mycophenolate</a>, <a href="/books/n/livertox/Sirolimus/">Sirolimus</a>, <a href="/books/n/livertox/Tacrolimus/">Tacrolimus</a></p></div></div><div id="Cyclosporine.PRODUCT_INFORMATION"><h2 id="_Cyclosporine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Cyclosporine &#x02013; Generic, Neoral&#x000ae;, Sandimmune&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Dermatologic Agents; Transplant Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Cyclosporine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Cyclosporine.CHEMICAL_FORMULA_AND_STRUCT"><h2 id="_Cyclosporine_CHEMICAL_FORMULA_AND_STRUCT_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Cyclosporine.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548753/table/Cyclosporine.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Cyclosporine.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Cyclosporine.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_b_Cyclosporine.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_b_Cyclosporine.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_Cyclosporine.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_Cyclosporine.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cyclosporine</td><td headers="hd_b_Cyclosporine.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135005091" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">59865-13-3</a></td><td headers="hd_b_Cyclosporine.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C62-H111-N11-O12</td><td headers="hd_b_Cyclosporine.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135005091" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135005091" alt="image 135005091 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Cyclosporine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Cyclosporine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 17 February 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Cyclosporine.REF.zimmerman.1999">Zimmerman HJ. Cyclosporine. Oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 697-8.<div><i>(Expert review of hepatotoxicity published in 1999; cyclosporine therapy is associated with a high rate of cholestatic liver enzyme elevations ranging from 4-86% and occasional instances of cholestatic hepatitis, some features of which are reproducible in animal models; tacrolimus, sirolimus, and mycophenolate are not discussed).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.reuben.2013">Reuben A. Hepatotoxicity of immunosuppressive drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 569-92.<div><i>(Review of hepatotoxicity of immunosuppressive agents mentions that reports of hepatotoxicity of cyclosporine have decreased since the 1980s, perhaps because of monitoring of serum levels and lower doses used; liver injury from tacrolimus, sirolimus and mycophenolate is rare and usually rapidly reversible).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.krensky.2018">Krensky AM, Azzi JR, Hafler DA. Immnosuppressants and tolerogens. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 637-54.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.calne.1979.1033">Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, et al.  Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs, 32 kidneys, 2 pancreas, and 2 livers. <span><span class="ref-journal">Lancet. </span>1979;<span class="ref-vol">2</span>:1033–6.</span> [<a href="/pubmed/91781" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 91781</span></a>]<div><i>(Initial experience with cyclosporine in 34 transplant recipients; all but 2 patients had liver test abnormalities early after operation, mostly raised bilirubin and Alk P resolving with lowering dose).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.starzl.1981.486">Starzl TE, Klintmalm GB, Weil R 3rd, Porter KA, Iwatsuki S, Schroter GP, Fernandez-Bueno C, et al.  Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. <span><span class="ref-journal">Surg Gynecol Obstet. </span>1981;<span class="ref-vol">153</span>:486–94.</span> [<a href="/pmc/articles/PMC2671391/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2671391</span></a>] [<a href="/pubmed/6269238" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6269238</span></a>]<div><i>(Early experience in using cyclosporine in 66 renal transplant recipients; two patents were switched to azathioprine because of hepatotoxicity, and liver function abnormalities occurred in 13 patients [20%], but no details given).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.loertscher.1981.635">Loertscher R, Wenk M, Harder F, Brunner F, Follath F, Thiel G. Hyperbilirubinaemia and cyclosporin A levels in renal transplant patients. <span><span class="ref-journal">Lancet. </span>1981;<span class="ref-vol">2</span>:635–6.</span> [<a href="/pubmed/6116111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6116111</span></a>]<div><i>(Among 8 patients receiving cyclosporine after renal transplantation, there was only a loose association between bilirubin and cyclosporine levels, serum bilirubin being elevated in 5 patients and decreasing with dose reduction [peak 4.2 mg/dL]).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.laupacis.1981.1426">Laupacis A, Keown PA, Ulan RA, Sinclair NR, Stiller CR. Hyperbilirubinaemia and cyclosporin A levels. <span><span class="ref-journal">Lancet. </span>1981;<span class="ref-vol">2</span>:1426–7.</span> [<a href="/pubmed/6118798" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6118798</span></a>]<div><i>(4 of 21 renal transplant recipients developed elevations in serum bilirubin [1.1-4.5 mg/dL] 4-12 days after transplant, which correlated with higher cyclosporine levels).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.klintmalm.1981">Klintmalm GB, Iwatsuki S, Starzl TE. Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation 1981; 32:4 88-9. [<a href="/pmc/articles/PMC2962575/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2962575</span></a>] [<a href="/pubmed/7041349" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7041349</span></a>]<div><i>(Among 66 renal transplant recipients on cyclosporine, 13 [17%] had rise of bilirubin above 2.0 [range 2.1-4.5] mg/dL, with minimal or no change in ALT or Alk P, and all episodes were mild and easily managed by dose reduction).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.ferguson.1982.175">Ferguson RM, Rynasiewicz JJ, Sutherland DE, Simmons RL, Najarian JS. Cyclosporin A in renal transplantation: a prospective randomized trial. <span><span class="ref-journal">Surgery. </span>1982;<span class="ref-vol">92</span>:175–82.</span> [<a href="/pubmed/6285533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6285533</span></a>]<div><i>(Controlled trial of cyclosporine and prednisone vs azathioprine, prednisone and antilymphocyte globulin in 100 renal transplant patients, hepatotoxicity was uncommon and mild; 3 of 48 patients on cyclosporine had mild bilirubin elevations [1.6-2.5 mg/dL], which were rapidly reversible with dose adjustment).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.rodger.1983.451">Rodger S, Turney JH, Haynes I, McMaster P, Michael J, Adu D. Normal liver function in renal allograft recipients treated with cyclosporine. <span><span class="ref-journal">Transplantation. </span>1983;<span class="ref-vol">36</span>:451–2.</span> [<a href="/pubmed/6353712" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6353712</span></a>]<div><i>(Among 35 renal transplant recipients, liver test abnormalities arose in 8 including 4 of 21 on cyclosporine, but other causes were found to be the cause in all eight [infection or heart failure]).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.european_multicentre_trial_group.1983.986">European Multicentre Trial Group.  Cyclosporine in cadaveric renal transplantation: one-year follow-up of a multicentre trial. <span><span class="ref-journal">Lancet. </span>1983;<span class="ref-vol">2</span>:986–9.</span> [<a href="/pubmed/6138592" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6138592</span></a>]<div><i>(Controlled trial of cyclosporine vs azathioprine and corticosteroids in 232 transplant recipients showing improved graft survival with cyclosporine; "mild, clinically insignificant degrees of hepatic functional impairment were observed in some cyclosporine-treated patients").</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.canadian_multicenter_transplant_study_group.1983.809">Canadian Multicenter Transplant Study Group.  A randomized clinical trial of cyclosporine in cadaveric renal transplantation. <span><span class="ref-journal">N Engl J Med. </span>1983;<span class="ref-vol">309</span>:809–15.</span> [<a href="/pubmed/6350878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6350878</span></a>]<div><i>(Controlled trial of cyclosporine vs azathioprine and corticosteroids in 209 transplant recipients showing improved graft survival; 4 instances of hepatotoxicity occurred in cyclosporine recipients usually associated with high plasma levels).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.najarian.1983.2463">Najarian JS, Strand M, Fryd DS, Ferguson RM, Simmons RL, Ascher NL, Sutherland DER. Comparison of cyclosporine versus azathioprine-antilymphocyte globulin in renal transplantation. <span><span class="ref-journal">Transplant Proc. </span>1983;<span class="ref-vol">15</span>(4) Suppl 1:2463–8.</span></div></li><li><div class="bk_ref" id="Cyclosporine.REF.schade.1983.2757">Schade RR, Guglielmi A, van Thiel DH, Thompson ME, Warty V, Griffith B, Sanghvi A, et al.  Cholestasis in heart transplant recipients treated with cyclosporine. <span><span class="ref-journal">Transplant Proc. </span>1983;<span class="ref-vol">15</span>(4) Suppl 1:2757–60.</span></div></li><li><div class="bk_ref" id="Cyclosporine.REF.atkinson.1983.2761">Atkinson K, Biggs J, Dodds A, Concannon A. Cyclosporine-associated hepatotoxicity after allogeneic marrow transplantation in man: differentiation from other causes of posttransplant liver disease. <span><span class="ref-journal">Transplant Proc. </span>1983;<span class="ref-vol">15</span>(4) Suppl 1:2761–7.</span></div></li><li><div class="bk_ref" id="Cyclosporine.REF.cohen.1984.667">Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: a new immunosuppressive agent for organ transplantation. <span><span class="ref-journal">Ann Intern Med. </span>1984;<span class="ref-vol">101</span>:667–82.</span> [<a href="/pubmed/6385799" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6385799</span></a>]<div><i>(Review of mechanism of action, clinical experience and side effects of cyclosporine; elevations in serum bilirubin reported in 20% of patients on cyclosporine after transplant, enzyme elevations were uncommon and "clinically, hepatotoxicity has been of little significance").</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.palestine.1984.652">Palestine AG, Nussenblatt RB, Chan CC. Side effects of systemic cyclosporine in patients not undergoing transplantation. <span><span class="ref-journal">Am J Med. </span>1984;<span class="ref-vol">77</span>:652–6.</span> [<a href="/pubmed/6486141" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6486141</span></a>]<div><i>(Among 22 patients with autoimmune uveitis treated with cyclosporine, side effects were fewer and less severe than after transplantation; only one patient had elevations in serum bilirubin [peak 1.6 mg/dL] and aminotransferase elevations did not occur).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.welz.1984.1212">Welz A, Reichart B, Uberfuhr P, Kemkes B, Klinner W. Cyclosporine as the main immunosuppressant in clinical heart transplantation: correlation of hepatotoxicity and nephrotoxicity. <span><span class="ref-journal">Transplant Proc. </span>1984;<span class="ref-vol">16</span>:1212–3.</span> [<a href="/pubmed/6385381" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6385381</span></a>]<div><i>(Among 10 patients undergoing heart transplantation and receiving cyclosporine, five with preexisting hepatic congestion had higher cyclosporine levels and higher serum bilirubin levels than the 5 without preexisting liver abnormalities [mean peak 5.8 vs 1.3 mg/dL]).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.mckenzie.1985.822">McKenzie FN, Moses GC, Henderson AR. Routine "cardiac" and "hepatic" serum enzyme profiles in cardiac transplant patients treated with cyclosporine A: operative and postoperative findings. <span><span class="ref-journal">Clin Chem. </span>1985;<span class="ref-vol">31</span>:822–5.</span> [<a href="/pubmed/2859934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2859934</span></a>]<div><i>(Prospective study of liver test abnormalities in 20 heart transplant recipients receiving cyclosporine found that transient elevations in ALT and AST were common during the 2 weeks after transplant).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.jensen.1987.263">Jensen CW, Flechner SM, Van Buren CT, Frazier OH, Cooley DA, Lorber MI, Kahan BD. Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin. <span><span class="ref-journal">Transplantation. </span>1987;<span class="ref-vol">43</span>:263–70.</span> [<a href="/pubmed/3544386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3544386</span></a>]<div><i>(Concurrent erythromycin led to elevations in cyclosporine levels and more toxicity in 9 transplant recipients, median serum bilirubin levels being 1.2 before, 2.1 during and 0.8 mg/dL after a course of the macrolide antibiotic).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.stone.1987.344">Stone BG, Udani M, Sanghvi A, Warty V, Plocki K, Bedetti CD, Van Thiel DH. Cyclosporin A-induced cholestasis. The mechanism in a rat model. <span><span class="ref-journal">Gastroenterology. </span>1987;<span class="ref-vol">93</span>:344–51.</span> [<a href="/pubmed/3596172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3596172</span></a>]<div><i>(In rats, cyclosporine led to decrease in bile flow [35%] and rise in serum bile acid levels without change in ALT or bilirubin).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.kahan.1987.197">Kahan BD, Flechner SM, Lorber MI, Golden D, Conley S, Van Buren CT. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. <span><span class="ref-journal">Transplantation. </span>1987;<span class="ref-vol">43</span>:197–204.</span> [<a href="/pubmed/3544376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3544376</span></a>]<div><i>(Retrospective analysis of complications of cyclosporine in 402 renal transplant recipients; 50% had at least one liver test abnormality in first month, 20% at one year and 10% at 3 years; no details given).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.lorber.1987.35">Lorber MI, Van Buren CT, Flechner SM, Williams C, Kahan BD. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. <span><span class="ref-journal">Transplantation. </span>1987;<span class="ref-vol">43</span>:35–40.</span> [<a href="/pubmed/3541320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3541320</span></a>]<div><i>(Among 466 patients undergoing renal transplantation, 49% developed liver test abnormalities after transplant [bilirubin in 48%, ALT 73%, Alk P 59%], but abnormalities were usually early [&#x0003c;90 days], mild and self-limiting; among 32 with persistent abnormalities, 11 had cholelithiasis).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.gulbis.1988.1772">Gulbis B, Adler M, Ooms HA, Desmet JM, Leclerc JL, Primo G. Liver-function studies in heart-transplant recipients treated with cyclosporin A. <span><span class="ref-journal">Clin Chem. </span>1988;<span class="ref-vol">34</span>:1772–4.</span> [<a href="/pubmed/2901299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2901299</span></a>]<div><i>(Prospective study of liver tests in 17 heart transplant recipients found rises in bile acid and GGT levels only, which occurred only in those with preexisting liver injury).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.cadranel.1988.234">Cadranel JF, Grippon P, Mattei MF, Lunel F, Pauwels A, Rossant P, Karkouche B, et al.  Prevalence and causes of long-lasting hepatic dysfunction after heart transplantation: a series of 80 patients. <span><span class="ref-journal">Artif Organs. </span>1988;<span class="ref-vol">12</span>:234–8.</span> [<a href="/pubmed/3291831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3291831</span></a>]<div><i>(Among 80 heart transplant recipients, 62% had persistent liver test abnormalities, usually due to heart failure [9%], hepatitis B [26%], non-A, non-B hepatitis [28%] and drug [not cyclosporine] induced liver injury [14%]).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.kassianides.1990.693">Kassianides C, Nussenblatt R, Palestine AG, Mellow SD, Hoofnagle JH. Liver injury from cyclosporine A. <span><span class="ref-journal">Dig Dis Sci. </span>1990;<span class="ref-vol">35</span>:693–7.</span> [<a href="/pubmed/2344802" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2344802</span></a>]<div><i>(Retrospective analysis of liver test abnormalities arising in 59 patients with autoimmune uveitis being treated with cyclosporine; persistent biochemical evidence of mild cholestasis [Alk P and bilirubin elevations] occurred in 32% of patients, but was usually self-limited and asymptomatic, improving spontaneously or with dose modification in all cases).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.rush.1991.101">Rush DN. Cyclosporine toxicity to organs other than the kidney. <span><span class="ref-journal">Clin Biochem. </span>1991;<span class="ref-vol">24</span>:101–5.</span> [<a href="/pubmed/2060127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2060127</span></a>]<div><i>(Review of mechanism of toxicity of cyclosporine; hyperbilirubinemia may be caused by inhibition of bile flow).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.wisecarver.1992.611">Wisecarver JL, Earl RA, Haven MC, Timmins PW, Shaw BW Jr, Stratta RJ, Langnas AN, et al.  Histologic changes in liver allograft biopsies associated with elevated whole blood and tissue cyclosporine concentrations. <span><span class="ref-journal">Mod Pathol. </span>1992;<span class="ref-vol">5</span>:611–6.</span> [<a href="/pubmed/1369795" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1369795</span></a>]<div><i>(Among 16 patients on cyclosporine after liver transplantation, histology of liver showed minor abnormalities of bile duct epithelium).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.demetris.1992.1056">Demetris AJ, Fung JJ, Todo S, McCauley J, Jain A, Takaya S, Alessiani M, et al.  Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy - a clinicopathologic study of 96 patients. <span><span class="ref-journal">Transplantation. </span>1992;<span class="ref-vol">53</span>:1056–62.</span> [<a href="/pmc/articles/PMC2962565/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2962565</span></a>] [<a href="/pubmed/1374944" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1374944</span></a>]<div><i>(Switching patients from cyclosporine to tacrolimus often improved acute rejection, but rarely improved chronic liver injury or suspected hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.mor.1994.380">Mor E, Sheiner PA, Schwartz ME, Emre S, Guy S, Miller CM. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. <span><span class="ref-journal">Transplantation. </span>1994;<span class="ref-vol">58</span>:380–2.</span> [<a href="/pubmed/7519800" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7519800</span></a>]<div><i>(Severe side effects of tacrolimus therapy requiring dose modification or switching to cyclosporine occurred in 15 of 90 patients [17%] including nephropathy, diabetes and neuropathy, but not hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.jazzar.1994.2654">Jazzar A, Fagiuoli S, Caraceni P, Deal S, Wright HI, Sisson S, Gavaler J, et al.  Incidence and etiology of hepatic dysfunction in heart transplant recipients receiving a cyclosporine-based triple immunosuppressive therapy. <span><span class="ref-journal">Transplant Proc. </span>1994;<span class="ref-vol">26</span>:2654.</span> [<a href="/pubmed/7940829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7940829</span></a>]<div><i>(Among 100 heart transplant recipients, 52 had abnormal liver tests, causes being viral hepatitis in 27%, azathioprine in 54%, unknown in 23% which were usually mild and spontaneously reversible).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.kowdley.1995.991">Kowdley KV, Keeffe EB. Hepatotoxicity of transplant immunosuppressive agents. <span><span class="ref-journal">Gastroenterol Clin North Am. </span>1995;<span class="ref-vol">24</span>:991–1001.</span> [<a href="/pubmed/8749908" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8749908</span></a>]<div><i>(Review of reports of hepatotoxicity from cyclosporine in form of mild hyperbilirubinemia, mild-to-moderate serum enzyme elevations and biliary sludge and stones).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.moore.1995.843">Moore RA, Greenberg E, Tangen L. Cyclosporine-induced worsening of hepatic dysfunction in a patient with Crohn's disease and enterocutaneous fistula. <span><span class="ref-journal">South Med J. </span>1995;<span class="ref-vol">88</span>:843–4.</span> [<a href="/pubmed/7631211" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7631211</span></a>]<div><i>(44 year old man with severe Crohn disease on total parenteral nutrition [TPN] developed marked bilirubin rises after starting cyclosporine [from 4.7 to 17.5 mg/dL], which resolved upon stopping both cyclosporine and TPN).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.ert_rer.1997.368">Ert&#x000f6;rer ME, Payda&#x0015f; S, Sagliker Y. Hyperbilirubinemia in a renal transplant patient due to cyclosporin A therapy. <span><span class="ref-journal">Nephron. </span>1997;<span class="ref-vol">76</span>:368.</span> [<a href="/pubmed/9226250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9226250</span></a>]<div><i>(50 year old male renal transplant recipient developed jaundice and fever [bilirubin 6.0 mg/dL, ALT 20 U/L, Alk P 263 U/L], resolving on stopping cyclosporine and recurring 3 months after restarting [bilirubin 3.4 mg/dL, ALT 72 U/L, Alk P 400 U/L], resolving within 2 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.tsamandas.1997.252">Tsamandas AC, Jain AB, Felekouras ES, Fung JJ, Demetris AJ, Lee RG. Central venulitis in the allograft liver: a clinicopathologic study. <span><span class="ref-journal">Transplantation. </span>1997;<span class="ref-vol">64</span>:252–7.</span> [<a href="/pubmed/9256183" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9256183</span></a>]<div><i>(Among 27 patients with central venulitis receiving cyclosporine or tacrolimus, there was no association with drug levels and the histological lesion was attributed to rejection rather than drug induced liver injury).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.ngo.1999.1873">Ngo MD, Hag&#x000e8; H, Rosa I, Cartier VA, Lons T, Gordin J, Chousterman M. <span><span class="ref-journal">Presse Med. </span>1999;<span class="ref-vol">28</span>:1873–5.</span> [Acute hepatitis in the course of cyclosporine therapy of Crohn's disease] French. [<a href="/pubmed/10587720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10587720</span></a>]<div><i>(26 year old woman with Crohn's disease on total parenteral nutrition developed marked rises in ALT [30 times ULN] and minimal increase in Alk P and bilirubin 1 week after starting cyclosporine, resolving within 2 weeks of stopping; multiple other drugs given).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.yuan.2000.1694">Yuan QS, Zheng FL, Sun Y, Yu Y, Li Y. Rescue therapy with tacrolimus in renal graft patients with cyclosporine A-induced hepatotoxicity: a preliminary study. <span><span class="ref-journal">Transplant Proc. </span>2000;<span class="ref-vol">32</span>:1694–5.</span> [<a href="/pubmed/11119896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11119896</span></a>]<div><i>(7 renal transplant recipients with suspected cyclosporine hepatotoxicity were switched to tacrolimus, ALT levels decreased from 28-119 to 24-43 U/L; no mention of bilirubin, Alk P or symptoms).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.emre.2000.73">Emre S, Genyk Y, Schluger LK, Fishbein TM, Guy SR, Sheiner PA, Schwartz ME, et al.  Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. <span><span class="ref-journal">Transpl Int. </span>2000;<span class="ref-vol">13</span>:73–8.</span> [<a href="/pubmed/10743694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10743694</span></a>]<div><i>(Among 388 liver transplant recipients treated with tacrolimus, 70 required conversion to cyclosporine because of side effects, including 6 for late hepatotoxicity, often for steatohepatitis or recurrent autoimmune hepatitis, with improvement in 4).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.russo.2004.1018">Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. <span><span class="ref-journal">Liver Transpl. </span>2004;<span class="ref-vol">10</span>:1018–23.</span> [<a href="/pubmed/15390328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15390328</span></a>]<div><i>(Among ~50,000 liver transplants reported to UNOS between 1990 and 2002, 270 [0.5%] were done for drug induced acute liver failure, 124 for acetaminophen and 137 for other drugs or toxins, but none for agents used to prevent transplant rejection).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.ganschow.2006.220">Ganschow R, Albani J, Grabhorn E, Richter A, Burdelski M. Tacrolimus-induced cholestatic syndrome following pediatric liver transplantation and steroid-resistant graft rejection. <span><span class="ref-journal">Pediatr Transplant. </span>2006;<span class="ref-vol">10</span>:220–4.</span> [<a href="/pubmed/16573611" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16573611</span></a>]<div><i>(Among 112 children undergoing liver transplantation and switched from cyclosporine to tacrolimus because of steroid resistant rejection, 6 [5.4%] developed a cholestatic syndrome within 2 weeks of change of medications).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.taniai.2008.187">Taniai N, Akimaru K, Ishikawa Y, Kanada T, Kakinuma D, Mizuguchi Y, Mamada Y, et al.  Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. <span><span class="ref-journal">J Nippon Med Sch. </span>2008;<span class="ref-vol">75</span>:187–91.</span> [<a href="/pubmed/18648179" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18648179</span></a>]<div><i>(56 year old liver transplant recipient developed fluctuating ALT elevations [averaging 200-300 U/L] and bilirubin elevations [peak 11 mg/dL] that were not explained by rejection or infection and appeared to respond transiently to changing from tacrolimus to cyclosporine and then recurring, ultimately treated with lower doses of tacrolimus and mycophenolate).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, none were attributed to cyclosporine, tacrolimus, sirolimus or mycophenolate).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none to an agent used to prevent transplant rejection).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.bj_rnsson.2013.1419">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, none of which were attributed to an anti-rejection agent used in transplantation).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, one was attributed to mycophenolate but none to cyclosporine, sirolimus or tacrolimus).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.ko.2015.363">Ko MS, Choi YH, Jung SH, Lee JS, Kim HS, Lee CH, Kim SG. Tacrolimus therapy causes hepatotoxicity in patients with a history of liver disease. <span><span class="ref-journal">Int J Clin Pharmacol Ther. </span>2015;<span class="ref-vol">53</span>:363–71.</span> [<a href="/pubmed/25740263" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25740263</span></a>]<div><i>(Analysis of electronic medical records from 2462 Korean patients with a history of liver taking tacrolimus or cyclosporine from 2002-2008, found that peak ALT levels were higher [50 vs 41 U/L] and time to peak was shorter [101 vs 142 days] in the tacrolimus treated patients).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.chalasani.2015">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. e7. [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, one case was attributed to cyclosporine, but none to tacrolimus, sirolimus or mycophenolate mofetil).</i></div></div></li><li><div class="bk_ref" id="Cyclosporine.REF.fiore.2018.3140983">Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. <span><span class="ref-journal">Biomed Res Int. </span>2018;<span class="ref-vol">2018</span>:3140983. </span> [<a href="/pmc/articles/PMC5818942/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5818942</span></a>] [<a href="/pubmed/29546055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29546055</span></a>]<div><i>(Review of liver disease in psoriasis including drug induced liver injury due to methotrexate, acitretin, TNF inhibitors, cyclosporine, and leflunomide).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548753</span><span class="label">PMID: <a href="/pubmed/31644062" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31644062</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Cycloserine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Cyproheptadine/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548753&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548753/?report=reader">PubReader</a></li><li><a href="/books/NBK548753/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548753" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548753" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Cyclosporine. [Updated 2020 Feb 17].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548753/pdf/Bookshelf_NBK548753.pdf">PDF version of this page</a> (123K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(cyclosporine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Cyclosporine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=cyclosporine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Cyclosporine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4859088" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4859088" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4859088" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643862" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tacrolimus</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tacrolimus<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643360" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Sirolimus</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Sirolimus<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644164" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Everolimus</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Everolimus<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643905" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Muromonab-CD3</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Muromonab-CD3<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643625" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Transplant Agents</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Transplant Agents<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31644062" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31644062" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:40:32-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D1D850466438100000000057101AC&amp;ncbi_session=CE8D1D850467DAE1_1393SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548753%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548753&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548753/&amp;ncbi_pagename=Cyclosporine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D1D850467DAE1_1393SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>